
Inmode Ltd (INMD) Stock Forecast & Price Target
Inmode Ltd (INMD) Analyst Ratings
Bulls say
InMode Ltd has demonstrated robust operational performance with the sale of 971 systems in Q2 2025, contributing to a global installed base growth to approximately 28,855 units, showcasing a 3.4% increase from the previous quarter. The company reported an operating margin of 27.5%, which surpassed expectations and reflected a year-over-year improvement of 40 basis points. Additionally, InMode's domestic sales reached $49.7 million in Q2 2025, indicating a positive reversal with a 9% growth from a decline of 7% in Q1 2025, driven by increasing consumer and physician engagement in the aesthetics market.
Bears say
InMode Ltd is facing a negative outlook primarily due to expected contraction in its profit margins, which, despite being among the highest in the med tech sector, are anticipated to decline. Additionally, the company's earnings per share (EPS) growth is projected to lag behind its revenue growth, indicating a potential inefficiency in translating revenue gains into profitability. Furthermore, a bear case scenario suggests a revenue compound annual growth rate (CAGR) of less than 5% over the next few years, driven by both weaker growth from existing products and slow adoption of new offerings.
This aggregate rating is based on analysts' research of Inmode Ltd and is not a guaranteed prediction by Public.com or investment advice.
Inmode Ltd (INMD) Analyst Forecast & Price Prediction
Start investing in Inmode Ltd (INMD)
Order type
Buy in
Order amount
Est. shares
0 shares